Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Herbamuno+ is a multi-ingredient herbal supplement developed by the Indonesian company PT Mustika Ratu Tbk. It is formulated as an immunomodulator to support the immune system, specifically investigated as an adjuvant therapy for patients with moderate COVID-19. The combination consists of five traditional Indonesian medicinal plants: Sambiloto (*Andrographis paniculata*), Akar Manis (*Glycyrrhiza glabra*), Meniran (*Phyllanthus niruri*), Jahe Emprit (*Zingiber officinale var. amarum*), and Daun Jambu Mete (*Anacardium occidentale*). These ingredients are selected for their synergistic anti-inflammatory, analgesic, hepatoprotective, and bronchodilator properties. The product received guidance from the Indonesian Food and Drug Authority (BPOM) and has undergone clinical evaluation at the RSDC Wisma Atlet Kemayoran to assess its efficacy in improving clinical outcomes and inflammatory markers in COVID-19 patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Herbamuno+.